Jefferies Financial Group Reiterates “Buy” Rating for Hikma Pharmaceuticals (LON:HIK)

Hikma Pharmaceuticals (LON:HIK)‘s stock had its “buy” rating reissued by analysts at Jefferies Financial Group in a research report issued on Friday, MarketBeat.com reports. They presently have a GBX 2,360 price objective on the stock. Jefferies Financial Group’s price target points to a potential upside of 49.18% from the company’s current price.

Other equities research analysts also recently issued research reports about the stock. Berenberg Bank lowered their price objective on shares of Hikma Pharmaceuticals from GBX 2,560 to GBX 2,510 and set a “buy” rating on the stock in a research note on Thursday, October 16th. JPMorgan Chase & Co. decreased their price target on shares of Hikma Pharmaceuticals from GBX 2,600 to GBX 2,500 and set an “overweight” rating on the stock in a research report on Friday, August 8th. Finally, Deutsche Bank Aktiengesellschaft dropped their price objective on shares of Hikma Pharmaceuticals from GBX 3,100 to GBX 2,850 and set a “buy” rating on the stock in a report on Tuesday, August 12th. Five investment analysts have rated the stock with a Buy rating, According to MarketBeat.com, the company has a consensus rating of “Buy” and an average target price of GBX 2,416.

Hikma Pharmaceuticals Stock Up 3.9%

Shares of Hikma Pharmaceuticals stock traded up GBX 60 during trading on Friday, hitting GBX 1,582. 1,155,675 shares of the stock traded hands, compared to its average volume of 1,297,659. The company has a fifty day moving average price of GBX 1,734.94 and a two-hundred day moving average price of GBX 1,896.07. Hikma Pharmaceuticals has a twelve month low of GBX 1,522 and a twelve month high of GBX 2,360. The stock has a market cap of £3.50 billion, a P/E ratio of 9.47, a PEG ratio of 2.38 and a beta of 0.41. The company has a debt-to-equity ratio of 55.82, a quick ratio of 1.27 and a current ratio of 1.66.

Insiders Place Their Bets

In other Hikma Pharmaceuticals news, insider Mazen Darwazah acquired 315,000 shares of Hikma Pharmaceuticals stock in a transaction dated Thursday, November 6th. The stock was bought at an average cost of GBX 1,601 per share, with a total value of £5,043,150. Also, insider Laura Balan Balan bought 3,500 shares of the firm’s stock in a transaction dated Friday, August 22nd. The shares were acquired at an average price of GBX 1,821 per share, for a total transaction of £63,735. In the last 90 days, insiders bought 332,500 shares of company stock valued at $533,130,500. Corporate insiders own 17.77% of the company’s stock.

About Hikma Pharmaceuticals

At Hikma we help put better health within reach, every day. By creating high-quality medicines and making them accessible to the people who need them, we help to shape a healthier world that enriches all our communities. We help deliver this by living our culture, delivering our strategy, and acting responsibly.